undamentalytics Newsletter
Sign in

Voyager Therapeutics, Inc. income statement

In fiscal 2025, Voyager Therapeutics, Inc. reported revenue of $40.4m, down 49.5% on the year before, operating income of −$132m (a -326.6% margin) and net income of −$120m, or −$2.04 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue17141081041713741250804034
Research and development28426265120109746192127135118
General and administrative101320343635373136363833
Operating income−20−41−72−91−5227−74−51122−83−132−117
Income before tax−30−40−71−88−4437−71−46134−64−120−108
Income tax00—−0———01100
Net income−30−40−71−88−4437−71−46132−65−120−108
Diluted EPS$9.14−$1.59−$2.64−$2.75−$1.21$0.98−$1.89−$1.21$2.97−$1.13−$2.04−$1.81
Diluted shares (average)4m25m27m32m36m37m38m38m45m58m59m59m
EBITDA−20−41−70−89−4931−68−45126−79−128−113

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: BHST vs VYGRCCCC vs VYGRFHTX vs VYGR

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Voyager Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Voyager Therapeutics, Inc.